Guardant Health (GH) Valuation After Japan ENHERTU Approval Backed By InfinityAI Real World Evidence

Guardant Health (GH) is back in focus after Japan’s Ministry of Health, Labour and Welfare approved ENHERTU for certain HER2 positive advanced solid cancers, supported in part by real world evidence from the company’s InfinityAI platform.

See our latest analysis for Guardant Health.

The InfinityAI backed ENHERTU approval arrives at a time when Guardant Health’s 1 year total shareholder return of 131.22% contrasts with a year to date share price return of 7.77% decline. This suggests longer term momentum, while the recent 90 day share price performance of 7.77% decline has been softer.

If this mix of AI and oncology has your attention, it could be a good moment to scan for other healthcare names using artificial intelligence in meaningful ways through the 36 healthcare AI stocks

With Guardant Health posting a 1 year total return of 131.22% while trading at an estimated 46.09% discount to intrinsic value and 39.23% below analyst targets, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 28.2% Undervalued

Guardant Health’s most followed valuation narrative sets fair value at $130.64 per share, compared with the last close at $93.83. This frames a sizeable implied discount before even factoring in the recent ENHERTU news.

Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's "Smart Liquid Biopsy" platform is creating new clinical applications, enhancing product utility and differentiation versus peers, which is leading to higher average selling prices (ASPs), rising margins, and increased potential for broader payer reimbursement and improved net margins.

Read the complete narrative.

Curious what assumptions sit behind that fair value gap? The narrative leans on rapid top line expansion, margin uplift, and a future earnings profile that looks very different from today.

Result: Fair Value of $130.64 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh ongoing net losses of US$416.3m and high cash burn, as well as reimbursement or payer adoption setbacks that could quickly challenge this upside case.

Find out about the key risks to this Guardant Health narrative.

Another View: Sales Multiple Sends A Different Signal

That 28.2% undervaluation story sits awkwardly next to Guardant Health’s price tag of 12.5x sales, compared with 1.2x for the broader US Healthcare group and a fair ratio of 5.8x. Put simply, the stock looks rich on revenue, so is the upside case already on the table?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing mixed signals on value and expectations so far? Take a moment to review the numbers, weigh both sides, and then check the 3 key rewards and 3 important warning signs.

Ready For Your Next Investment Idea?

If Guardant Health has sharpened your thinking, do not stop here. Use the Simply Wall St screener to spot other opportunities before the crowd leans in.

• Target quality at a discount by scanning companies that look mispriced on fundamentals with the 59 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by focusing on companies highlighted in the 68 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with solid metrics before they hit every headline using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com